A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results

ConclusionsIn subjects receiving vedolizumab in addition to standard GvHD prophylaxis, there were no DLTs or engraftment failures at 6 months after HCT, and the TEAEs observed have been as expected in this population. The low cumulative incidences of grade II-IV and grade III-IV aGvHD are promising; there were no cases of lower GI aGvHD greater than stage 1. Intravenous vedolizumab 300 mg added to standard GvHD prophylaxis for the prevention of GI aGvHD merits further study.DisclosuresChen: Takeda Pharmaceuticals: Consultancy; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Consultancy; REGiMMUNE: Consultancy. Shah: Lentigen Technology: Research Funding; Oncosec: Equity Ownership; Exelexis: Equity Ownership; Miltenyi: Other: Travel funding, Research Funding; Juno Pharmaceuticals: Honoraria; Geron: Equity Ownership. Jansson: Takeda Pharmaceuticals: Employment. Akbari: Takeda Pharmaceuticals: Employment. Chen: Takeda Pharmaceuticals: Employment. Quadri: Takeda Pharmaceuticals: Employment. Parfionovas: Takeda Pharmaceuticals: Employment. Devine: Kiadis Pharma: Consultancy.

Source: Blood - November 21, 2018 Category: Hematology Authors: Chen, Y.-B., Shah, N. N., Renteria, A. S., Cutler, C. S., Jansson, J., Akbari, M., Chen, C., Quadri, S., Parfionovas, A., Devine, S. Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: GVHD Treatment and Prevention Strategies Source Type: research